Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lenalidomide-rituximab or lenalidomide-rituximab-bendamustine for relapsed/refractory follicular lymphoma: primary and final analysis of the randomized phase II HOVON110/ReBeL study.

Haematologica·2026

Same author

Predicting long-term absolute risk of lung cancer in Hodgkin lymphoma patients.

Journal of the National Cancer Institute·2026

Same author

Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.

Journal of the National Cancer Institute·2026

Same author

Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry.

Open forum infectious diseases·2026

Same author

Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS-COV-2-A Report From the EPICOVIDEHA/EPIRESEHA Registry.

American journal of hematology·2025

Same author

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.

Blood advances·2025

Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026

Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026

Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026

Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026

Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026

Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 30, 2026

Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector

Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector

Published on: October 31, 2012

Plerixafor for stem cell mobilization: the current status.

Yavuz M Bilgin¹, Georgine E de Greef

¹aDepartment of Internal Medicine, Admiraal de Ruyter Hospital, Goes/Vlissingen bDepartment of Hematology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.

Current Opinion in Hematology

|November 12, 2015

Summary

This summary is machine-generated.

Plerixafor effectively mobilizes CD34+ cells for stem cell transplantation in patients unresponsive to conventional methods. Its optimal use and cost-effectiveness require further investigation.

More Related Videos

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Published on: February 15, 2019

Related Experiment Videos

Last Updated: Mar 30, 2026

Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector

Generation of Human Induced Pluripotent Stem Cells from Peripheral Blood Using the STEMCCA Lentiviral Vector

Published on: October 31, 2012

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Published on: February 15, 2019

Area of Science:

Hematology
Pharmacology
Oncology

Background:

Plerixafor is approved for patients failing to mobilize sufficient CD34+ cells for autologous stem cell transplantation.
It effectively treats patients who would otherwise be untreatable.

Purpose of the Study:

To review the current status and optimal use of plerixafor in various clinical settings.
To evaluate plerixafor's efficacy in different patient populations and diagnoses.

Main Methods:

Review of existing clinical data and strategies for plerixafor use.
Analysis of patient responses and tolerability across different settings.

Main Results:

Plerixafor shows greater efficacy in multiple myeloma compared to lymphoma.
Significant benefit observed even in patients with very low baseline CD34+ cell counts.
Multiple strategies demonstrate effective responses, with no single strategy proving superior.
Plerixafor is well-tolerated with acceptable toxicity but is expensive.

Conclusions:

Plerixafor is effective for patients failing conventional mobilization strategies.
No specific strategy is definitively superior for plerixafor administration.
Further research on plerixafor's kinetics and cost-effectiveness is warranted.